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Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and pre-
vention strategies. Our aimwas to develop PRSs, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest avail-
able genome-wide association dataset and to empirically validate the PRSs in prospective studies. The development dataset comprised
94,075 case subjects and 75,017 control subjects of European ancestry from 69 studies, divided into training and validation sets. Samples
were genotyped using genome-wide arrays, and single-nucleotide polymorphisms (SNPs) were selected by stepwise regression or lasso
penalized regression. The best performing PRSs were validated in an independent test set comprising 11,428 case subjects and 18,323
control subjects from 10 prospective studies and 190,040 women from UK Biobank (3,215 incident breast cancers). For the best PRSs
(313 SNPs), the odds ratio for overall disease per 1 standard deviation in ten prospective studies was 1.61 (95%CI: 1.57–1.65) with
area under receiver-operator curve (AUC) ¼ 0.630 (95%CI: 0.628–0.651). The lifetime risk of overall breast cancer in the top centile
of the PRSs was 32.6%. Compared with women in the middle quintile, those in the highest 1% of risk had 4.37- and 2.78-fold risks,
and those in the lowest 1% of risk had 0.16- and 0.27-fold risks, of developing ER-positive and ER-negative disease, respectively. Good-
ness-of-fit tests indicated that this PRS was well calibrated and predicts disease risk accurately in the tails of the distribution. This PRS is a
powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.Introduction
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The Amwas 0.86. Samples were included on the basis of female sex
(genetic and self-reported) and ethnicity filter (Europeans/White
British ancestry subset). Duplicates, individuals with high degree
of relatedness (>10 relatives), and one of each related pair of first
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standard quality control criteria.
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were approved by the relevant ethics committees, and procedures
followed were in accordance with the ethical standards of these
committees.Statistical Analysis
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PRS ¼ b1x1 þ b2x2 þ.þ bkxk.þ bnxn
where bk is the per-allele log odds ratio (OR) for breast cancer
associated with SNP k, xk is the allele dosage for SNP k, and n is
the total number of SNPs included in the PRS. Previous analyses
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SNPs19,20 and little evidence for departures from a log-additive
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the PRS summarizes efficiently the combined effects of SNPs on
disease risk.
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SNPs reaching a stringent significance threshold (‘‘genome-wide
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approaches for model selection: ‘‘hard-thresholding,’’ based on a
stepwise regression model that retained SNPs significantly associ-
ated with overall or subtype-specific disease at a given threshold,
and penalized regression using lasso.21,22 A schema for the ana-
lyses is shown in Figure S1.
To prioritize SNPs for analysis, single SNP association tests were
first conducted in the training set. Per-allele ORs and standard er-
rors were estimated separately in the iCOGS and OncoArray data-
sets, adjusting for study and nine ancestry informative principal
components (PCs) in the iCOGS dataset and by country and ten
PCs in the OncoArray dataset, using a purpose-written program.1
Combined p values were then derived using a fixed-effects
meta-analysis with the software METAL.23 SNPs were sorted by
p value and filtered on LD, such that uncorrelated SNPs (correla-
tion r2 < 0.9) with lowest p value for association with overall
breast cancer in the training set were retained (more rigorous
pruning, for example at r2 < 0.2, would have removed from
consideration informative SNPs from regions with multiple corre-
lated signals24,25).
In the hard thresholding approach, a series of stepwise forward
regression analyses were first carried out in 1 Mb regions centered
on SNPs significant at a pre-specified threshold for association
with either overall and/or subtype-specific disease in the training
set. Only SNPs passing the specified p value thresholds were
included in each 1 Mb region. Two analyses were performed in
parallel: for overall breast cancer and ER-negative disease. At
each stage the SNP with the smallest (conditional) p value for
any analysis was added to the model, the threshold for the step-
wise regression being the same as that for pre-selection. The pro-
cess was repeated until no further SNPs could be added at the
pre-defined threshold. A second stage of stepwise regressions
were then carried out across all regions in each chromosome, to
take into account correlated SNPs in different regions. Finally,
the effect sizes for the selected SNPs were jointly estimated in a
single logistic regression model.
For the best-performing PRSs, SNPs associated with ER-positive
at p < 106 but not with overall breast cancer (at p < 105) were
added at the end of the final SNP list. A third round of stepwise
forward regression was then carried out with p value for selection
of p < 106 for ER-positive disease. For completeness we added to
this final PRS two rarer variants (BRCA2 p.Lys3326X and CHEK2
p.Ile157Tyr) which are established to confer a moderate risk of
breast cancer and were genotyped on the OncoArray but did
not pass the allele frequency threshold in the PRS development
phase.
For the penalized regression using lasso, we used the program
glmnet 21. SNPs with p< 0.001 in overall BC or ER-negative disease
in the training set were pre-selected for inclusion in the lasso, and
BRCA2 p.Lys3326X and CHEK2 p.Ile157Thr were added. Covari-
ates for 19 PCs (9 for iCOGs and 10 for Oncoarray) and country
were included in eachmodel. For overall breast cancer, the penalty
parameter (lambda) giving the best overall breast cancer PRS in the
validation set was selected.
To construct subtype-specific PRSs, we evaluated four different
methods: (1) using effect sizes for overall breast cancer (for each
of the subtypes), (2) using effect sizes for subtype-specific (ER-pos-
itive or ER-negative) disease, (3) using a hybrid method, in which
effect sizes were estimated in the relevant subtype for SNPs passing
a certain optimal significance threshold in a case-only logistic
regression (ER-positive versus ER-negative disease), and otherwise,
using effect sizes estimated for overall breast cancer, or (4) by esti-
mating case-only ORs using lasso and combining these with the26 The American Journal of Human Genetics 104, 21–34, January 3, 2overall breast cancer ORs to derive subtype-specific estimates,
using the formulae:
bERpositive ¼ boverall þ h  bcaseonly
bERnegative ¼ boverall  ð1 hÞ  bcaseonly
where h ¼ 0.27 was the proportion of ER-negative tumors in the
validation set.
For the lasso analysis, effect sizes for subtype-specific disease were
estimated using method 4 above, combining the estimates from
a case-only lasso analysis with the coefficients for overall breast
cancer from the lasso analysis. The lambda for the case-onlymodel
giving the best subtype-specific PRS in the validation set was
selected.
To evaluate the performance of each potential PRS, we standard-
ized the PRSs to have unit standard deviation (SD) in the valida-
tion set of control subjects. The association of the standardized
PRSs was evaluated in the validation and test (prospective studies)
datasets, by logistic regression. We used a Cox proportional haz-
ards regression model to assess the association with risk of breast
cancer in UK Biobank. Models were also compared in terms of
the area under the receiver operator characteristic curves (AUC),
adjusted for study, calculated using the Stata command comproc.
Meta-analysis of study-specific effects was carried out using the
Stata command metan.
The goodness of fit of the continuous model (i.e., assuming a
linear association between log(OR) and risk) was tested using the
Hosmer-Lemeshow (HL) test to compare the observed and pre-
dicted risks by quantile and using the tail-based test proposed by
Song et al.26 In addition, we considered specifically the risks in
the highest and lowest 1% of the distribution.
Effect modification of the PRS by age and family history of
breast cancer in first-degree relatives was evaluated by fitting
additional interaction terms in the model. The validation and
prospective test datasets were combined for this analysis.
The absolute risks of developing breast cancer (overall and
subtype-specific disease) were calculated taking into account the
competing risk of dying from causes other than breast cancer, as
described previously,7 with the PRS modeled as a continuous
covariate and including a linear ‘‘age 3 PRS’’ interaction term.
The absolute risk of developing subtype-specific disease was
obtained constraining to the incidence of overall incidence of
ER-negative and ER-positive disease in the UK. Women are at
risk of developing both ER-negative and ER-positive disease, so
the absolute risks were calculated given that the individual has
been free of breast cancer of any subtype.
Analyses were carried out in R v.3.0.2 and Stata v.14.2. All tests
of statistical significance were two-sided. Further details are pro-
vided in the Supplemental Material and Methods.Results
Development of the PRS
We tried several approaches to develop PRSs; here we
report results for models giving the highest prediction
accuracy. Using stepwise forward selection, the best PRS
for prediction of overall breast cancer was obtained at a
p value threshold for pre-selection and stepwise regression
of p < 105 (Table 1). The OR per unit standard deviation
(SD) for this 305-SNP PRS with overall breast cancer in019
Table 1. Comparison of Methods for Deriving the PRS: Results for Overall Breast Cancer in the Validation Set
p Value Cutoffa SNPs Entering Model (n) SNPs Selected (n) ORb 95% CI AUC
Published PRS7
77 77 1.49 1.44–1.56 0.612
Hard-Thresholding Stepwise Forward Regression
<5 3 108 1,817 123 1.59 1.52–1.66 0.626
<106 2,603 197 1.62 1.55–1.68 0.634
<105 3,818 305 1.65 1.58–1.72 0.637
<104 6,743 669 1.62 1.56–1.69 0.631
<103 14,760 1,707 1.55 1.49–1.62 0.623
Penalized Regression
Lasso 15,032 3,820 1.71 1.64–1.79 0.647
aThe p value cut off refers to the SNPs considered based on their marginal associations in the training set; the same p value threshold was used in each case in the
stepwise regression. Parameter selection and effect size estimation for derivation of the PRS was carried out in the training set as described in the Material and
Methods.
bOR per 1 SD for the PRS. OR for association with breast cancer in the validation set was derived using logistic regression adjusting for country and ten PCs. AUCs
were adjusted for country. The lasso was carried out after pre-selecting SNPs at p < 103 based on their marginal association in the training set. For the lasso
l ¼ 0.003 gave the optimal PRS in the validation set.the validation set was 1.65 (95%CI: 1.58–1.72), compared
with 1.59 (95%CI: 1.52–1.66) using a ‘‘genome-wide’’
(p < 5 3 108) threshold (123 SNPs).
Using lasso regression, the best PRS (OR ¼ 1.71, 95%CI:
1.64–1.79) was more predictive than the best PRS devel-
oped using the stepwise regression model. In the best
model (l ¼ 0.003), 3,820 SNPs were selected (Table 1).
Optimizing the PRS for Prediction of Subtype-Specific
Disease
For evaluation of subtype-specific models following step-
wise regression, SNP effect sizes were estimated, in the first
instance, in each disease subtype. The best subtype-specific
PRSs using this method were also obtained at a p value
threshold of p < 105 (Table S5). The 305-SNP PRS was
supplemented with 6 additional SNPs associated with
ER-positive at p value < 106 and, in addition, by two
known rare breast cancer susceptibility variants in the
BRCA2 and CHEK2 genes, bringing the total number of
SNPs included to 313 (PRS313).
The optimum subtype-specific PRS was obtained when a
subset of these 313 SNPs (196 SNPs with a case-only p value
for association with ER-negative versus ER-positive disease
of p < 0.025) were given subtype-specific weights, while
the remaining SNPs were given overall breast cancer
weights. For ER-negative disease, the OR improved from
OR ¼ 1.45 (95%CI: 1.35–1.56) to OR ¼ 1.47 (95%CI:
1.37–1.58) using the hybrid method compared with using
only subtype-specific estimates, while for ER-positive dis-
ease the results were similar (OR¼ 1.74) (Tables S6 and S7).
Subtype-specific prediction using the lasso analysis
was optimized using case-only lasso analysis. The OR
per 1 SD in the validation set was 1.81 (95%CI: 1.73–
1.89) for ER-positive and 1.48 (95%CI: 1.37–1.59) for ER-
negative disease (Tables 2 and S8).The AmValidation of the PRS in the Prospective Test Dataset
The final PRSs were evaluated using data from 11,428 inva-
sive breast cancer-affected case subjects and 18,323 control
subjects from ten prospective studies. The ORs for both the
overall and subtype-specific PRSs were slightly lower in the
prospective test set compared to the validation set (Table 2).
The difference between validation and test set may reflect
some overfitting due to choosing the optimum p value
threshold and for the lasso, the optimum lambda, in the
validation set, but could also be due to somewhat different
characteristics of the prospective studies. The ORs for over-
all and ER-positive, but not ER-negative, breast cancer were
slightly higher for the 3,820-SNP PRS (PRS3820) compared
with PRS313.
The odds ratio (OR) for overall disease per 1 standard de-
viation (SD) of the PRS313 in the prospective studies was
1.61 (95%CI: 1.57–1.65) while for the 77-SNP PRS (PRS77)
derived previously OR ¼ 1.46 (95%CI: 1.42–1.49). For ER-
negative disease the difference was OR ¼ 1.45 (95%CI:
1.37–1.53) versus 1.35 (95%CI: 1.27–1.43) (Table 2).
The associations between the PRS and overall, ER-
positive, and ER-negative breast cancer by percentiles of
the PRS313 are shown in Figure 1 and Table S9. Compared
with women in the middle quintile (40th to 60th percen-
tile), those in the highest 1% of risk for the subtype-specific
PRS313 had 4.37 (95%CI: 3.59–5.33)- and 2.78 (95%CI:
1.83–4.24)-fold risks, and those in the lowest 1% had
0.16 (95%CI: 0.09–0.30)- and 0.27 (95%CI: 0.09–0.86)-
fold risks of developing ER-positive and ER-negative dis-
ease, respectively. The ORs by percentile of the PRS3820
were similar (Table S10).
Goodness of Fit of the PRS
The remaining analyses concentrated on PRS313. The
associations between the PRS and breast cancer risk byerican Journal of Human Genetics 104, 21–34, January 3, 2019 27
Table 2. Association between PRS and Breast Cancer Risk in the Validation Set and Prospective Test Datasets
Validation Set Prospective Test Set
ORa 95% CI AUC ORa 95% CI AUC
77 SNP PRS (PRS77)
Overall BC 1.49 1.44–1.56 0.612 1.46 1.42–1.49 0.603
ER-positive 1.56 1.49–1.63 0.623 1.52 1.48–1.56 0.615
ER-negative 1.40 1.30–1.50 0.596 1.35 1.27–1.43 0.584
313 SNP PRS (PRS313)
Overall BC 1.65 1.59–1.72 0.639 1.61 1.57–1.65 0.630
ER-positive 1.74 1.66–1.82 0.651 1.68 1.63–1.73 0.641
ER-negative 1.47 1.37–1.58 0.611 1.45 1.37–1.53 0.601
3,820 SNP PRS (PRS3820)
Overall BC 1.71 1.64–1.79 0.646 1.66 1.61–1.70 0.636
ER-positive 1.81 1.73–1.89 0.659 1.73 1.68–1.78 0.647
ER-negative 1.48 1.37–1.59 0.611 1.44 1.36–1.53 0.600
Parameter selection and effect size estimation for derivation of the PRS was carried out in the training set as described in the Material and Methods. The optimal
subtype-specific PRS was obtained by carrying out case-only logistic regression and estimating effect sizes in the relevant subtype for SNPs passing a p value of
0.025 in case-only ordinary logistic regression (ER-positive versus ER-negative disease). OR for association with breast cancer in the validation set derived using
logistic regression adjusting for country and ten PCs. AUCs were adjusted for by country. In the prospective test set, logistic regression models were adjusted
for study and 15 PCs. AUCs were adjusted for by study.
aOR per 1 SD for the PRS.percentiles of the risk score were compared with those
predicted under a simple polygenic model with the PRS
considered as a continuous covariate. The effect sizes
did not differ from those predicted, and in particular
the estimates for the highest and lowest centile were
consistent with the predicted estimates (Table S9).
Further tests for goodness of fit and tail-based tests (see
Material and Methods) were not statistically significant
at p < 0.05.
There was no evidence of heterogeneity in the effect
sizes among studies (Figure 2). All studies showed a signif-
icant association with similar effect sizes for overall and
ER-positive breast cancer, and all but one study (FHRISK,
based on only six case subjects) showed a significant effect
for ER-negative breast cancer.
In the UK Biobank, the estimated hazard ratio (HR) for
overall breast cancer per unit PRS (including 306 of the
313 SNPs) was HR ¼ 1.59 (95%CI: 1.54–1.64) (Figure 2).
By way of comparison, we also evaluated a PRS based on
177 previously published susceptibility loci.1,2 The effect
size for this PRS (OR ¼ 1.61, 95%CI: 1.57–1.65) in the
ten prospective studies was similar to the PRS313. However,
this estimated effect size is biased because the validation
and test datasets used here contributed to the GWAS
discovery datasets; in the UK Biobank this PRS (based on
174 of 177 available SNPs) performed worse (HR ¼ 1.53,
95%CI: 1.48–1.58).PRS Effects by Age
Aweak decline in the ORwith age was observed for ER-pos-
itive disease (p ¼ 0.001, for the combined validation and28 The American Journal of Human Genetics 104, 21–34, January 3, 2test set). There was some evidence that the decline in PRS
OR was not linear, driven by a lower estimate below age
40 years (Table S11, Figure S2). There was no evidence
of a decline in the OR by age for ER-negative disease
(p ¼ 0.39).Combined Effects of PRS and Breast Cancer Family
History
The association between PRS and disease risk was observed
for women with and without a family history (Table 3).
However, there was some evidence that for ER-positive dis-
ease, the PRS OR was smaller in women with a family his-
tory (interaction OR ¼ 0.91, p ¼ 0.004). The log OR for
family history was attenuated by 21% (1.59 to 1.44) and
12% (1.66 to 1.56) for ER-positive and ER-negative disease,
respectively, after adjusting for the PRS (Tables 3 and S12).Absolute Risk of Developing Breast Cancer According to
the PRS
Estimated lifetime and 10-year absolute risks for UK
women in percentiles of the PRS are shown in Figure 3.
For ER-positive disease, the estimated lifetime absolute
risk by age 80 years ranged from 2% for women in the
lowest centile to 31% in the highest centile, while for
ER-negative disease, the absolute risks ranged from 0.55%
to 4%. The average 10-year absolute risk of breast cancer
for a 47-year-old woman (i.e., the age at which women
become eligible to enter the UK breast cancer screening
program) in the general population is 2.6%. However,
the 19% of women with the highest PRSs will attain this
level of risk by age 40 years.019
Figure 2. Prospective Validation for the 313 SNP Polygenic Risk
Score
Prospective validation for the 313 SNP polygenic risk score (PRS)
by study for (A) overall breast cancer, (B) ER-positive disease, and
(C) ER-negative disease. Association between the 313 SNP PRS
and breast cancer risk in women of European origin. Odds ratios
and 95% confidence intervals are shown. I-squared and p value
for heterogeneity were calculated using fixed effect meta-analysis.
Figure 1. Association between the 313 SNP Polygenic Risk Score
and Breast Cancer Risk
Association between the 313 SNP polygenic risk score (PRS) and
breast cancer risk in women of European origin for (A) overall
breast cancers, (B) estrogen receptor (ER)-positive disease, and
(C) ER-negative disease, in the validation (dashed line) and test
(solid line) sets. Odds ratios are for different quantiles of the PRS
relative to the mean PRS. Odds ratios and 95% confidence inter-
vals are shown.Discussion
We report development and independent validation of
polygenic risk scores for breast cancer, optimized for pre-
diction of subtype-specific disease and based on the largest
available GWAS dataset. The best PRS based on a hard
thresholding approach included 313 SNPs and was signifi-The Amcantly more predictive of risk than the previously reported
77-SNP PRS7 (OR per 1 SD in the prospective test set:
1.61 versus 1.46; Table 2). The effect sizes were remarkablyerican Journal of Human Genetics 104, 21–34, January 3, 2019 29
Table 3. Associations between the 313-SNP PRS (PRS313) and Breast Cancer Risk by First-Degree Family History of Breast Cancer in the
Combined Validation and Prospective Test Dataset
Model
ER-Positive Disease ER-Negative Disease
ORa 95% CI ORa 95% CI
Association of PRS and Breast Cancer Risk by Family History
PRS unadjusted 1.67 1.62–1.72 1.44 1.37–1.54
PRS in women without family history 1.71 1.65–1.78 1.45 1.36–1.57
PRS in women with family history 1.55 1.48–1.65 1.40 1.27–1.55
Interaction between PRS and family history 0.91 0.85–0.97 (p ¼ 0.004) 0.96 0.85–1.09 (p ¼ 0.53)
Association between Family History and Breast Cancer Risk (Adjusted and Unadjusted for PRS)
Family history unadjusted for PRS 1.59 1.46–1.72 1.66 1.41–1.95
Family history adjusted for PRS 1.44 1.33–1.57 1.56 1.32–1.83
Association with breast cancer risk was tested for using logistic regression adjusting for study and ten PCs. For these analyses the validation and test datasets were
combined. Analyses were restricted to women with known age and family history information. For ER-negative disease, 4,440 women with and 13,132 women
without a family history of breast cancer were included in these analyses. For ER-positive disease, 6,787 women with and 17,351 women without a family history of
breast cancer were included in these analyses.
aOR per 1 SD for the PRS.consistent among the 10 cohorts in the prospective test
set, and also consistent with that in the UK Biobank cohort
(HR ¼ 1.59, 95%CI: 1.54–1.64).
Recently, Khera et al.27 derived a PRS using our publicly
available summary statistics based on analysis of the BCAC
data.1 We were able to construct a PRS based on 5,194 of
their 5,218 listed SNPs and compared this to our 313-SNP
PRS. In our analysis of this PRS in the prospective UK Bio-
bank data, we obtained a HR of 1.49 (95%CI: 1.44–1.54),
substantially lower than that for our PRS313. The corre-
sponding AUCs were 0.613 (95%CI: 0.603–0.623) for their
5,194-SNP PRS versus AUC 0.630 (95%CI: 0.620–0.640) for
PRS313. Similarly, PRS313 performed better than the Khera
et al. PRS in a Biobank dataset consisting of 7,113 case sub-
jects diagnosed before entry and 183,536 control subjects
(AUC ¼ 0.642 versus AUC ¼ 0.627). Khera et al. report a
much higher AUC (0.68), perhaps reflecting the inclusion
of predictors other than SNPs in their model (for example
age or principal components).
We specifically aimed to improve prediction for ER-nega-
tive breast cancer as to date prediction of this more aggres-
sive disease has been poor. SNP selection was based on
association with either ER-negative or overall breast can-
cer, and the optimum subtype-specific PRSs were derived
by weighting a subset of SNPs according to subtype-specific
effect sizes, with overall breast cancer weights used for the
remaining SNPs. These results are consistent with the
observation from genome-wide analyses that the heritabil-
ity of ER-positive and ER-negative disease are partially
correlated.2 The performance of the PRS313 in predicting
ER-negative disease was considerably improved over the
PRS77 reported previously (OR ¼ 1.45 versus 1.35). Never-
theless, the prediction is still better for ER-positive than
ER-negative disease, reflecting the fact that ER-negative
disease is more infrequent and hence the GWAS data are
less powerful. The estimated heritability of ER-negative dis-30 The American Journal of Human Genetics 104, 21–34, January 3, 2ease is similar to that of overall breast cancer,1,2 suggesting
that more powerful ER-negative PRSs should be achievable
with larger sample sizes.
The best PRS developed using lasso was more predictive
for ER-positive disease but slightly less predictive for
ER-negative disease in the prospective studies. Given the
small differences between the models, we focused on
PRS313 since this should be more straightforward to imple-
ment in diagnostic laboratories using next generation
sequencing. However, this will change with developing
technology, and the cost effectiveness of using a large
marker panel should be further investigated.
From a clinical viewpoint, an important consideration
is the performance of the PRS in the tails of the distribu-
tion. According to the standard polygenic model, under
which the effects of variants combine multiplicatively,
the relationship between the PRS and the log-OR should
be linear. The PRS was well calibrated at different quan-
tiles. Even in this large study, we observed no deviation
from this model, and in particular the observed risks in
the highest and lowest centile were consistent with the
predicted risk. The sample sizes in the extreme tails, how-
ever, were still relatively small, particularly for ER-negative
disease.
While the AUC may appear modest, the predicted risk
differences in the tails of the distribution are large. For
the new PRS313, the women in the top 1% of the distribu-
tion have a predicted risk that is approximately 4-fold
larger than the risk in the middle quintile. The lifetime
risk of overall breast cancer in the top centile of the PRSs,
based on UK incidence and mortality data, was 32.6%.
Women in the top centile would therefore meet the UK
NICE definition of high risk (see Web Resources). In the
general population, an estimated 3.6%, 12%, 21%, and
35% of all breast cancers would be expected to occur in
women in the highest 1%, 5%, 10%, and 20% of the new019
Figure 3. Cumulative and 10-Year Absolute Risk of Developing Breast Cancer
Cumulative and 10-year absolute risk of developing breast cancer for (A) overall breast cancer, (B) ER-positive disease, and (C) ER-nega-
tive disease by percentiles of the 313 SNP polygenic risk scores (PRSs). Note different scales and PRS categories in the different panels. The
red line shows the 2.6% risk threshold corresponding to the mean risk for women aged 47 years. Absolute risks were calculated based on
UK incidence and mortality data and using the PRS relative risks estimated as described in the Material and Methods.PRS313, respectively, compared to only 9% of breast cancers
in women in the lowest 20% of the distribution.
We observed a decline in the relative risk with age for
ER-positive disease but not ER-negative disease. Even for
ER-positive disease, however, the predicted relative risk,
under a linear model, only declined from 1.89 at age 40
to 1.67 at age 70. While there was some indication of a
lower relative risk below age 40 (estimated as 1.63 in the
test set; Figure S2), these results indicate that PRS313 is
broadly applicable at all ages. We observed an attenuation
of the association between breast cancer family history and
breast cancer risk after adjustment for the PRS (21% forThe AmER-positive, 12% for ER-negative disease). This finding
is broadly in line with the predicted contribution of the
PRS to the familial relative risk of breast cancer. The PRS
was predictive in women with and without a family his-
tory of breast cancer, but the OR was slightly lower in
women with a family history, at least for ER-positive dis-
ease. This might reflect a weaker relative effect of the PRS
in carriers of BRCA1 or BRCA2mutations.28 We note, how-
ever, that the absolute differences in risk by PRS will be
larger in women with a family history. These results indi-
cate that the joint effects of family history and PRS need
to be considered in risk prediction.erican Journal of Human Genetics 104, 21–34, January 3, 2019 31
Although we used the largest training dataset available
to date for development of the PRS, further improvement
should still be possible. We previously estimated using
GWAS data that the theoretically best PRS, if the effect sizes
of all common SNPs were known with certainty, would
explain 41% of the familial risk of breast cancer, corre-
sponding to a standardized OR2.1: the PRS313 explains
45% of this ‘‘chip’’ heritability.1 This implies that larger
GWASs, coupled with penalized approaches for subtype-
specific disease, should further improve the predictive
value of the PRS. Certain genomic features, notably tran-
scription factor binding sites, are enriched among suscep-
tibility loci.1 Preliminary analyses incorporating these
features into the analysis did not improve the predictive
value, presumably because the enrichment effect was too
small to overcome the increased complexity of the model.
Better definition of genomic features to predict causal
variants, and more sophisticated methods for integrating
external biological information into prediction models,
may improve the PRS.29,30
The PRS has the potential to improve stratification for
screening,while ER-specific PRSsmaybe informative for pre-
ventionwith endocrine therapies. Previous studieshave sug-
gested that the earlier PRS77 was more predictive for screen-
detected breast cancers than interval cancers, and that breast
cancers arising among women with a low PRS are more
aggressive compared with those arising in women with a
high PRS, perhaps reflecting the stronger associations with
ER-positivedisease.31,32 Itwill thereforebe important toeval-
uate carefully the associations between the new PRS313 and
other tumor characteristics. Clinical translational studies
are required to assess the risks and benefits of including the
PRS in the context of current screening protocols.
While the PRS provides powerful risk discrimination,
better risk discrimination will be obtained by combining
the PRS with family history and other risk factors.10 This
can be accomplished by incorporating the PRS into risk
prediction models, in particular BOADICEA, which can
allow for the explicit effects of family history, age, genetic,
and other risk factors33,34 (see Supplemental Material and
Methods). However, further studies to validate risk models
for individualized risk prediction based on the combined
effects of genetic and lifestyle risk factors will be needed.
In addition, it is important to note that the PRSs generated
in this study were developed and validated in white Euro-
pean populations and need to be validated and potentially
adapted for other populations.Accession Numbers
Requests for access to this dataset should be made to the BCAC co-
ordinator, contact provided in Web Resources.Supplemental Data
Supplemental Data include 2 figures, 12 tables, Supplemental Ac-
knowledgments, and Supplemental Material and Methods and32 The American Journal of Human Genetics 104, 21–34, January 3, 2can be found with this article online at https://doi.org/10.1016/
j.ajhg.2018.11.002.Consortia
ABCTB Investigators are Christine Clarke, Rosemary Balleine, Rob-
ert Baxter, Stephen Braye, Jane Carpenter, Jane Dahlstrom, John
Forbes, C. Soon Lee, Deborah Marsh, Adrienne Morey, Nirmala
Pathmanathan, Rodney Scott, Peter Simpson, Allan Spigelman,
Nicholas Wilcken, Desmond Yip, and Nikolajs Zeps.
kConFab/AOCS Investigators are Adrienne Sexton, Alex Dobrovic,
Alice Christian, Alison Trainer, Allan Spigelman, Andrew Fellows,
Andrew Shelling, Anna De Fazio, Anneke Blackburn, Ashley
Crook, BettinaMeiser, Briony Patterson, Christine Clarke, Christo-
bel Saunders, Clare Hunt, Clare Scott, David Amor, David Gallego
Ortega, DebMarsh, Edward Edkins, Elizabeth Salisbury, Eric Haan,
Finlay Macrea, Gelareh Farshid, Geoff Lindeman, Georgia Trench,
GrahamMann, Graham Giles, Grantley Gill, Heather Thorne, Ian
Campbell, Ian Hickie, Liz Caldon, Ingrid Winship, James Cui,
James Flanagan, James Kollias, Jane Visvader, Jennifer Stone, Jes-
sica Taylor, Jo Burke, Jodi Saunus, John Forbes, John Hopper, Jona-
than Beesley, Judy Kirk, Juliet French, Kathy Tucker, Kathy Wu,
Kelly Phillips, Laura Forrest, Lara Lipton, Leslie Andrews, Lizz
Lobb, Logan Walker, Maira Kentwell, Mandy Spurdle, Margaret
Cummings, Margaret Gleeson, Marion Harris, Mark Jenkins,
Mary Anne Young, Martin Delatycki, Mathew Wallis, Matthew
Burgess, Melissa Brown, Melissa Southey, Michael Bogwitz,
Michael Field, Michael Friedlander, Michael Gattas, Mona Saleh,
Morteza Aghmesheh, Nick Hayward, Nick Pachter, Paul Cohen,
Pascal Duijf, Paul James, Pete Simpson, Peter Fong, Phyllis Butow,
Rachael Williams, Rick Kefford, Rodney Scott, Roger Milne, Rose-
mary Balleine, Sarah-Jane Dawson, Sheau Lok, Shona O’Connell,
Sian Greening, Sophie Nightingale, Stacey Edwards, Stephen
Fox, Sue-Anne McLachlan, Sunil Lakhani, Tracy Dudding, and Yo-
land Antill.
NBCS collaborators are Kristine K. Sahlberg, Lars Ottestad, Rolf
Ka˚resen, Ellen Schlichting, Marit Muri Holmen, Toril Sauer, Vilde
Haakensen, Olav Engebra˚ten, Bjørn Naume, Alexander Fossa˚, Ce-
cile E. Kiserud, Kristin V. Reinertsen, A˚slaug Helland, Margit Riis,
Ju¨rgen Geisler, and OSBREAC.Acknowledgments
BCAC was funded by Cancer Research UK (C1287/A16563) and
by the European Community’s Seventh Framework Programme
under grant agreement no. 223175 (HEALTH-F2-2009-223175)
(COGS) and by the European Union’s Horizon 2020 Research
and Innovation Programme under grant agreements 633784
(B-CAST) and 634935 (BRIDGES). Genotyping of the OncoArray
was principally funded by Government of Canada through
Genome Canada and the Canadian Institutes of Health Research
(grant GPH-129344), the Ministe`re de l’E´conomie, de la Science
et de l’Innovation du Que´bec through Genome Que´bec, the
Quebec Breast Cancer Foundation; NIH grants U19 CA148065
and X01HG007492; and Cancer Research UK (C1287/A10118
and C1287/A16563). Genotyping of the iCOGS array was funded
by the European Union (HEALTH-F2-2009-223175), Cancer
Research UK (C1287/A10710), the Canadian Institutes of Health
Research for the ‘‘CIHR Team in Familial Risks of Breast Cancer’’
program, and theMinistry of Economic Development, Innovation
and Export Trade of Quebec (grant # PSR-SIIRI-701). Combining
the GWAS data was supported in part by the National Institutes019
of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1
U19 CA 148065 (DRIVE, part of the GAME-ON initiative). We
thank all the individuals who took part in these studies and all
researchers, clinicians, technicians, and administrative staff who
enabled this work to be carried out. For other acknowledgments
and sources of funding, see Supplemental Acknowledgments.Declaration of Interests
D.G.E. reports grants from AstraZeneca and AmGen, outside the
submitted work; U.M. has stock ownership and has received
research funding from Abcodia Pvt Ltd.; A. Smeets reports other
from MSD, outside of the submitted work; P.A.F. reports grants
and personal fees from Novartis and personal fees from Pfizer,
Roche, Teva, and Celgene, outside the submitted work; R.C. de-
clares personal fees from Novartis, AstraZeneca, and Genentech,
outside the submitted work. B.R. reports funding for the conduct
of the clinical Success trial paid to her institution from
AstraZeneca, Chugai, Lilly, Novartis, Veridex (now Janssen Diag-
nostics), and Sanofi Aventis. M. Robson reports grants, personal
fees, and non-financial support from AstraZeneca, personal fees
fromMcKesson, grants and personal fees fromPfizer, non-financial
support from Myriad, non-financial support from Invitae, and
grants fromAbbVie, Tesaro, andMedivation, outside the submitted
work; andM.P.L. reports personal fees fromNovartis, Pfizer, Roche,
Teva, AstraZeneca, Lilly, and Eisai, outside the submitted work.
Received: August 9, 2018
Accepted: November 3, 2018
Published: December 13, 2018Web Resources
BCAC data access, http://bcac.ccge.medschl.cam.ac.uk
BCAC Summary statistics, http://bcac.ccge.medschl.cam.ac.uk/
bcacdata/oncoarray/gwas-icogs-and-oncoarray-summary-
results/
CORDIS, https://cordis.europa.eu/project/rcn/212694_en.html
GenomeCanada 2018 projects, https://www.genomecanada.ca/
sites/default/files/2017lsarp_backgrounder_en.pdf
NICE, familial breast cancer clinical guidelines (accessed June 4,
2018), http://guidance.nice.org.uk/CG164
Nomis (26 March 2018), https://www.nomisweb.co.uk/
Office of National Statistics, https://www.ons.gov.uk/
West Midlands Cancer Intelligence Unit, http://www.wmciu.
nhs.uk/References
1. Michailidou, K., Lindstro¨m, S., Dennis, J., Beesley, J., Hui, S.,
Kar, S., Lemac¸on, A., Soucy, P., Glubb, D., Rostamianfar, A.,
et al.; NBCS Collaborators; ABCTB Investigators; and
ConFab/AOCS Investigators (2017). Association analysis iden-
tifies 65 new breast cancer risk loci. Nature 551, 92–94.
2. Milne, R.L., Kuchenbaecker, K.B., Michailidou, K., Beesley, J.,
Kar, S., Lindstro¨m, S., Hui, S., Lemac¸on, A., Soucy, P., Dennis,
J., et al.; ABCTB Investigators; EMBRACE; GEMO Study Col-
laborators; HEBON; kConFab/AOCS Investigators; and NBSC
Collaborators (2017). Identification of ten variants associated
with risk of estrogen-receptor-negative breast cancer. Nat.
Genet. 49, 1767–1778.The Am3. Pashayan, N., Duffy, S.W., Chowdhury, S., Dent, T., Burton,
H., Neal, D.E., Easton, D.F., Eeles, R., and Pharoah, P.
(2011). Polygenic susceptibility to prostate and breast cancer:
implications for personalised screening. Br. J. Cancer 104,
1656–1663.
4. Hall, P., and Easton, D. (2013). Breast cancer screening: time to
target women at risk. Br. J. Cancer 108, 2202–2204.
5. Burton, H., Chowdhury, S., Dent, T., Hall, A., Pashayan, N.,
and Pharoah, P. (2013). Public health implications from
COGS and potential for risk stratification and screening.
Nat. Genet. 45, 349–351.
6. Torkamani, A., Wineinger, N.E., and Topol, E.J. (2018). The
personal and clinical utility of polygenic risk scores. Nat.
Rev. Genet. 19, 581–590.
7. Mavaddat, N., Pharoah, P.D., Michailidou, K., Tyrer, J., Brook,
M.N., Bolla, M.K., Wang, Q., Dennis, J., Dunning, A.M., Shah,
M., et al. (2015). Prediction of breast cancer risk based on
profiling with common genetic variants. J. Natl. Cancer Inst.
107, djv036. https://doi.org/10.1093/jnci/djv036.
8. Maas, P., Barrdahl, M., Joshi, A.D., Auer, P.L., Gaudet, M.M.,
Milne, R.L., Schumacher, F.R., Anderson, W.F., Check, D.,
Chattopadhyay, S., et al. (2016). Breast cancer risk frommodi-
fiable and nonmodifiable risk factors among white women in
the United States. JAMA Oncol. 2, 1295–1302.
9. Garcia-Closas, M., Gunsoy, N.B., and Chatterjee, N. (2014).
Combined associations of genetic and environmental risk fac-
tors: implications for prevention of breast cancer. J. Natl. Can-
cer Inst. 106, dju305. https://doi.org/10.1093/jnci/dju305.
10. Rudolph, A., Song, M., Brook, M.N., Milne, R.L., Mavaddat,
N., Michailidou, K., Bolla, M.K., Wang, Q., Dennis, J., Wilcox,
A.N., et al. (2018). Joint associations of a polygenic risk
score and environmental risk factors for breast cancer in the
Breast Cancer Association Consortium. Int. J. Epidemiol. 47,
526–536.
11. Evans, D.G., Astley, S., Stavrinos, P., Harkness, E., Donnelly,
L.S., Dawe, S., Jacob, I., Harvie, M., Cuzick, J., Brentnall, A.,
et al. (2016). Improvement in risk prediction, early detection
and prevention of breast cancer in the NHS Breast Screening
Programme and family history clinics: a dual cohort study.
Southampton UK: NIHR Journals Library (Programme Grants
for Applied Research, No. 4.11.), https://www.ncbi.nlm.nih.
gov/books/NBK379488/doi:10.3310/pgfar04110.
12. Shieh, Y., Eklund, M., Madlensky, L., Sawyer, S.D., Thompson,
C.K., Stover Fiscalini, A., Ziv, E., Van’t Veer, L.J., Esserman, L.J.,
Tice, J.A.; and Athena Breast Health Network Investigators
(2017). Breast cancer screening in the precision medicine
era: risk-based screening in a population-based trial. J. Natl.
Cancer Inst. 109. https://doi.org/10.1093/jnci/djw290.
13. Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S., Dennis,
J., Lush, M.J., Maranian, M.J., Bolla, M.K., Wang, Q., Shah, M.,
et al.; BOCS; kConFab Investigators; AOCS Group; NBCS; and
GENICA Network (2015). Genome-wide association analysis
of more than 120,000 individuals identifies 15 new suscepti-
bility loci for breast cancer. Nat. Genet. 47, 373–380.
14. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M.,
Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J., Boje-
sen, S.E., Bolla, M.K., et al.; Breast and Ovarian Cancer Suscep-
tibility Collaboration; Hereditary Breast and Ovarian Cancer
Research Group Netherlands (HEBON); kConFab Investiga-
tors; Australian Ovarian Cancer Study Group; and GENICA
(Gene Environment Interaction and Breast Cancer in
Germany) Network (2013). Large-scale genotyping identifieserican Journal of Human Genetics 104, 21–34, January 3, 2019 33
41 new loci associated with breast cancer risk. Nat. Genet. 45,
353–361, e1–e2.
15. Amos, C.I., Dennis, J., Wang, Z., Byun, J., Schumacher, F.R.,
Gayther, S.A., Casey, G., Hunter, D.J., Sellers, T.A., Gruber,
S.B., et al. (2017). The OncoArray Consortium: a network for
understanding the genetic architecture of common cancers.
Cancer Epidemiol. Biomarkers Prev. 26, 126–135.
16. Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang,
H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean,
G.A., Abecasis, G.R.; and 1000 Genomes Project Consortium
(2015). A global reference for human genetic variation. Nature
526, 68–74.
17. O’Connell, J., Gurdasani, D., Delaneau, O., Pirastu, N., Ulivi,
S., Cocca, M., Traglia, M., Huang, J., Huffman, J.E., Rudan,
I., et al. (2014). A general approach for haplotype phasing
across the full spectrum of relatedness. PLoS Genet. 10,
e1004234.
18. O’Connell, J., Sharp, K., Shrine, N., Wain, L., Hall, I., Tobin,
M., Zagury, J.F., Delaneau, O., and Marchini, J. (2016). Haplo-
type estimation for biobank-scale data sets. Nat. Genet. 48,
817–820.
19. Milne, R.L., Herranz, J., Michailidou, K., Dennis, J., Tyrer, J.P.,
Zamora, M.P., Arias-Perez, J.I., Gonza´lez-Neira, A., Pita, G.,
Alonso, M.R., et al.; kConFab Investigators; Australian
Ovarian Cancer Study Group; GENICA Network; and TNBCC
(2014). A large-scale assessment of two-way SNP interactions
in breast cancer susceptibility using 46,450 cases and 42,461
controls from the breast cancer association consortium.
Hum. Mol. Genet. 23, 1934–1946.
20. Joshi, A.D., Lindstro¨m, S., Hu¨sing, A., Barrdahl, M., Vander-
Weele, T.J., Campa, D., Canzian, F., Gaudet, M.M., Figueroa,
J.D., Baglietto, L., et al.; Breast and Prostate Cancer Cohort
Consortium (BPC3) (2014). Additive interactions between
susceptibility single-nucleotide polymorphisms identified in
genome-wide association studies and breast cancer risk factors
in the Breast and Prostate Cancer Cohort Consortium. Am. J.
Epidemiol. 180, 1018–1027.
21. Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regulariza-
tion paths for generalized linear models via coordinate
descent. J. Stat. Softw. 33, 1–22.
22. Tibshirani, R. (1996). Regression shrinkage and selection via
the Lasso. J. R. Stat. Soc. B 58, 267–288.
23. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and
efficient meta-analysis of genomewide association scans. Bio-
informatics 26, 2190–2191.
24. French, J.D., Ghoussaini, M., Edwards, S.L., Meyer, K.B., Mi-
chailidou, K., Ahmed, S., Khan, S., Maranian, M.J., O’Reilly,
M., Hillman, K.M., et al.; GENICA Network; and kConFab
Investigators (2013). Functional variants at the 11q13 risk lo-
cus for breast cancer regulate cyclin D1 expression through
long-range enhancers. Am. J. Hum. Genet. 92, 489–503.
25. Meyer, K.B., O’Reilly, M., Michailidou, K., Carlebur, S., Ed-
wards, S.L., French, J.D., Prathalingham, R., Dennis, J., Bolla,
M.K., Wang, Q., et al.; GENICA Network; kConFab Investiga-34 The American Journal of Human Genetics 104, 21–34, January 3, 2tors; and Australian Ovarian Cancer Study Group (2013).
Fine-scale mapping of the FGFR2 breast cancer risk locus: pu-
tative functional variants differentially bind FOXA1 and E2F1.
Am. J. Hum. Genet. 93, 1046–1060.
26. Song,M., Kraft, P., Joshi, A.D., Barrdahl, M., and Chatterjee, N.
(2015). Testing calibration of risk models at extremes of dis-
ease risk. Biostatistics 16, 143–154.
27. Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C.,
Choi, S.H., Natarajan, P., Lander, E.S., Lubitz, S.A., Ellinor, P.T.,
and Kathiresan, S. (2018). Genome-wide polygenic scores for
common diseases identify individuals with risk equivalent to
monogenic mutations. Nat. Genet. 50, 1219–1224.
28. Kuchenbaecker, K.B., McGuffog, L., Barrowdale, D., Lee, A.,
Soucy, P., Dennis, J., Domchek, S.M., Robson, M., Spurdle,
A.B., Ramus, S.J., et al. (2017). Evaluation of polygenic risk
scores for breast and ovarian cancer risk prediction in
BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst.
109. https://doi.org/10.1093/jnci/djw302.
29. Shi, J., Park, J.H., Duan, J., Berndt, S.T., Moy, W., Yu, K., Song,
L., Wheeler, W., Hua, X., Silverman, D., et al.; MGS (Molecular
Genetics of Schizophrenia) GWAS Consortium; GECCO
(The Genetics and Epidemiology of Colorectal Cancer
Consortium); GAME-ON/TRICL (Transdisciplinary Research
in Cancer of the Lung) GWAS Consortium; PRACTICAL
(PRostate cancer AssoCiation group To Investigate Cancer
Associated aLterations) Consortium; PanScan Consortium;
and GAME-ON/ELLIPSE Consortium (2016). Winner’s curse
correction and variable thresholding improve performance
of polygenic risk modeling based on genome-wide association
study summary-level data. PLoS Genet. 12, e1006493.
30. Pereira, M., Thompson, J.R., Weichenberger, C.X., Thomas,
D.C., and Minelli, C. (2017). Inclusion of biological knowl-
edge in a Bayesian shrinkage model for joint estimation of
SNP effects. Genet. Epidemiol. 41, 320–331.
31. Holm, J., Li, J., Darabi, H., Eklund, M., Eriksson, M., Hum-
phreys, K., Hall, P., and Czene, K. (2016). Associations of
breast cancer risk prediction tools with tumor characteristics
and metastasis. J. Clin. Oncol. 34, 251–258.
32. Li, J., Holm, J., Bergh, J., Eriksson, M., Darabi, H., Lindstro¨m,
L.S., To¨rnberg, S., Hall, P., and Czene, K. (2015). Breast cancer
genetic risk profile is differentially associated with interval
and screen-detected breast cancers. Ann. Oncol. 26, 517–522.
33. Lee, A.J., Cunningham, A.P., Kuchenbaecker, K.B., Mavaddat,
N., Easton, D.F., Antoniou, A.C.; Consortium of Investigators
of Modifiers of BRCA1/2; and Breast Cancer Association Con-
sortium (2014). BOADICEA breast cancer risk prediction
model: updates to cancer incidences, tumour pathology and
web interface. Br. J. Cancer 110, 535–545.
34. Macinnis, R.J., Antoniou, A.C., Eeles, R.A., Severi, G., Al
Olama, A.A., McGuffog, L., Kote-Jarai, Z., Guy, M., O’Brien,
L.T., Hall, A.L., et al. (2011). A risk prediction algorithm based
on family history and common genetic variants: application
to prostate cancer with potential clinical impact. Genet. Epi-
demiol. 35, 549–556.019
